Increasing the CpG levels in IE1 could also increase the immunogenicity of the virus by triggering more robust IFN responses, which could improve HCMV vaccines as well as the use of HCMV as a vaccine vector and as a therapeutic cancer vaccine. Here, IFNA1 is linked to cancer.